AGM Statement

Hikma Pharmaceuticals Plc
06 June 2007




              Annual General Meeting of Hikma Pharmaceuticals PLC


LONDON, 6 June 2007 - Hikma Pharmaceuticals PLC ('Hikma') (LSE: HIK) (DIFX:
HIK), the multinational pharmaceuticals manufacturer, will hold its Annual
General Meeting today in London. At the meeting, Samih Darwazah, Chairman and
Chief Executive of Hikma Pharmaceuticals PLC, will make the following statement:

'I am pleased to report that, as anticipated, the Group is performing well
year-to-date. We will announce our interim results for the six months ended 30
June 2007 on 5 September 2007 and will publish an update on trading at the end
of June, prior to entering our close period on 7 July 2007.'


                                    - ENDS -


Enquiries:

Hikma Pharmaceuticals PLC
Susan Ringdal                                     [phone]
Investor Relations Director


Brunswick Group
Jon Coles / Justine McIlroy / Alex Tweed          [phone]



About Hikma

Hikma Pharmaceuticals PLC is a multinational pharmaceutical group focused on
developing, manufacturing and marketing a broad range of both branded and
non-branded generic and in-licensed pharmaceutical products. Hikma's operations
are conducted through three businesses: Generic, Branded and Injectable
Pharmaceuticals. Hikma's operations are based principally in the Middle East and
North Africa ('MENA') region, the United States and Europe. In 2006, the Group
had revenue of $317 million and profit attributable to shareholders of $55
million. At 31 December 2006, the Group had over 2,443 employees. For news and
other information, please visit www.hikma.com.





                      This information is provided by RNS
            The company news service from the London Stock Exchange